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To ascertain adherence to an international consensus target of ≤7.5mg/day of prednisolone 
for maintenance systemic corticosteroid (CS) prescribing in uveitis and report the frequency 
of courses of high-dose systemic CS in the UK. 
 
Methods 
We conducted a national, multicentre audit of systemic CS prescribing for uveitis at 11 UK 
sites between November 2018 and March 2019. High-dose CS was defined as (1) 
maintenance >7.5mg prednisolone for >3 consecutive months, or (2) >1 course ≥40mg oral 
CS or ≥ 500mg intravenous (IV) methylprednisolone in the past 12 months. Case notes of 
patients exceeding threshold CS doses were reviewed by an independent uveitis specialist 
and judged as avoidable or not, based upon a scoring matrix. 
 
Results 
Of 667 eligible patients, 285 (42.7%) were treated with oral or IV CS over the preceding 12 
months; 96 (33.7%) of these exceeded the threshold for high-dose CS. Twenty-five percent of 
prescribing in patients on excess CS was judged avoidable; attributed to either prescribing 
long-term CS without evidence of consideration of alternative strategies, prescribing error or 
miscommunication. More patients received immunomodulatory therapy (IMT) in the group 
treated with CS above threshold than below threshold (p<0.001) but there was no significant 
difference in doses of IMT.  
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Conclusion  
33% of patients had been prescribed excessive corticosteroid when compared to the reference 
standard. An analysis of decision–making suggests there may be opportunity to reduce excess 


























Corticosteroids (CS) have been the mainstay of treatment for non-infectious uveitis (NIU) 
and scleritis since the middle of the 20th century. NIU is often a chronic disease characterised 
by remission and relapses affecting vision. Systemic CS are a highly effective first line in 
therapy which rapidly and inexpensively control active disease and prevent relapses. The 
medium and long-term risk profile of systemic CS is well-known and includes weight gain, 
thrombotic venous occlusions, hypertension, diabetes, osteoporosis and adrenal insufficiency. 
Within the eye, their use results in secondary complications such as glaucoma and 
cataract[1]. A daily oral prednisolone dose in excess of 7.5mg/day is associated with a greater 
than 2-fold increase in risk of cardiovascular events[2]. Although the exact relation between 
dose and adverse effects remains unknown, significant reductions in bone mineral density are 
associated with doses ≥5mg/day[1]. In the context of biologic therapies, a large registry study 
showed that the risk of infection was directly related to the dose of systemic CS[3].    
 
Consensus guidelines for NIU published in 2000 recommend a maximum maintenance (> 3 
consecutive months) dose of 10mg/day oral prednisolone and steroid-sparing 
immunomodulatory therapy (IMT) in patients requiring more than 10mg/day[4]. This 
principle was reiterated by an international consensus group, recommending IMT for relapses 
after reduction of oral CS dose to 7-10mg/day[5]. Other speciality groups within the UK, 
including rheumatology have guidelines for CS use in clinical practice to minimise the 
burden of side effects[6]. Consequently, a maintenance dose of ≤7.5mg/day CS, usually 
prednisolone in the UK, is considered an acceptable target for maintenance treatment by 
uveitis specialists and other physicians treating autoimmune diseases[6, 7]. However, 
adherence to a consensus target by practising uveitis specialists is unknown. High dose 
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systemic CS contribute to cumulative CS exposure[1] but no study to date has reported upon 
the frequency with which courses of high dose systemic CS are prescribed in uveitis.  
 
The Ocular Inflammation Steroid Toxicity Risk (OSTRICH) study was conducted to evaluate 
patterns of CS use in uveitis and scleritis through the UK National Uveitis Clinical Study 
Group[8], a clinical research network of uveitis specialists based within the UK. We wished 
to determine the proportion of patients prescribed excess of 7.5mg of prednisolone for 3 
months, and the number of episodes of high dose systemic CS use for relapses or poorly 




The OSTRICH study was conducted as a national, multicentre audit at eleven sites in the UK. 
All members of the UK Uveitis National Clinical Study Group[8], a national clinical research 
organisation for ophthalmologists managing uveitis patients in secondary and tertiary 
institutions, were invited to participate in this study. Ten out of eleven participating sites 
were tertiary uveitis centres, representing half of all tertiary centres in the UK.   
 
Institutional Caldicott Guardian approval was obtained at each site; ethical approval was not 
required by our institutional review board. The study was carried out in two phases; the 
output from Phase 1 was utilised in Phase 2. Anonymised site and subject data were collected 
and stored securely using a REDCap database (v8.10 © 2020 Vanderbilt University, 
Nashville, TN, USA) held at the University of Oxford[9, 10].  
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Phase 1: CS data collection 
 
We wished to determine the proportion of patients with non-infectious uveitis or scleritis who 
met criteria for excess systemic CS in the past 12 months. The criteria for excess CS were 1) 
a maintenance dose of >7.5mg prednisolone for >3 consecutive months or 2) >1 course of 
rescue CS therapy (≥40mg oral CS or ≥ 500mg intravenous methylprednisolone), in the past 
12 months. For the purposes of this study, we adopted a threshold of one course of high dose 
systemic CS per year from the British Society of Gastroenterology guidelines as 
acceptable[7].  
 
Uveitis specialists at eleven sites across the UK completed questionnaires for consecutive 
non-infectious uveitis and scleritis patients attending clinic for a 6-week period between 
November 2018 and March 2019. Data collected included diagnosis, the presence of active 
uveitis/scleritis, sight-threatening complications, and all treatments received in the past 12 
months (Table 1, Supplementary information). 
 
Subjects meeting eligibility criteria were 1) over 16 years old, 2) had a diagnosis of non-
infectious chronic anterior uveitis, intermediate uveitis, posterior uveitis, panuveitis or non-
infectious scleritis and 3) had been followed up for at least 6 months. Patients who were 
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Phase 2:  Scoring Matrix for CS Prescribing 
 
Case notes from a sample of 52 subjects in 5 sites, meeting the criteria for excess CS in the 
past 12 months, were reviewed by an independent uveitis expert, either at the same or a 
different site and were masked to identifying data if at a different site. The notes were placed 
in two categories: either avoidable or unavoidable excess steroid prescribing according to a 
scoring matrix. Table 1 shows the reasons for avoidable and unavoidable excess CS 
prescribing.  
 
Phase 1 and Phase 2 are summarised in the algorithm in Figure 1. 
 
Statistical Analysis 
Data were analysed using statistical software (R v3.3.3; R development Core Team 2013, 
University of Auckland, New Zealand)[11]. For non-parametric continuous data, between 
group comparisons were analysed using the Mann Whitney U test. Comparison of 
proportions between groups was analysed using Pearson’s Chi-squared test statistic. Alpha 




Phase 1  
Questionnaires completed by uveitis specialists for 892 patients from eleven different centres 
treating uveitis and scleritis patients were entered into Phase 1 of the study, of which 667 
(74.8%) fulfilled the eligibility criteria (Figure 1). The mean age of patients was 50.5 years 
(range: 17 – 94 years). Uveitis involving the posterior segment of the eye was present in 
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16.5% of patients and the most common cause of sight threatening disease was cystoid 
macular oedema (Table 2 patient demographics and clinical characteristics). 
 
A total of 285 subjects (42.7% of eligible patients) were treated with oral or intravenous CS 
in the past 12 months (Table 2, Supplementary Information).  We recorded several other 
treatments: immunomodulatory therapies (IMT) including biologic therapies (54.4%), 
intravitreal CS (6.4%), periocular CS (5.2%) and anti-VEGF therapies (1.7%).  
 
Analysis of patients on CS 
 
Out of 285 patients treated with CS in this study, 96 (33.7%) met the criteria for excess CS 
(Figure 1) after exclusion of 9 cases who were treated with high dose CS for other systemic 
indications. Of those, 84 (29.5%) were treated with a maintenance dose of >7.5mg 
prednisolone continuously for longer than 3-month period and 23 (8.1%) were treated with 
more than 1 course of high dose CS within a 12-month period (Figure 2). 
 
Both the median CS dose at the current consultation and the median maximum CS dose in the 
past 12 months were significantly higher in the group treated with CS above threshold (10mg and 
40mg respectively) than in the group treated with CS below threshold (5mg and 10mg 
respectively) (p<0.001, Mann Whitney U test). Of the 96 patients treated with CS above 
threshold, 82 (85.4%) had active uveitis in the past 12 months, compared with only 51.9% of 
those treated with CS below threshold (p<0.001, Pearson’s chi-squared test). Figure 2 shows the 
distribution of CS use over 12 months.  
 
Systemic Corticosteroid Use in UK Uveitis Practice… 
 10 
Panuveitis was the most common type of uveitis for those patients treated with CS, either 
above or below threshold. Of the patients treated with CS above threshold, 52.1% were also 
taking calcium and 19.8% were taking bisphosphonates, compared to 47.6% and 16.9% 
respectively in patients treated with sub-threshold CS (these differences were not statistically 
significant). We did not record vitamin D prescriptions. Cystoid macular oedema was the 
most common site-threatening feature. Cystoid macular oedema and peripheral retinal 
vasculitis were significantly more common in patients treated with CS above threshold than 
those treated below threshold (p=0.042, Pearson’s chi-squared test) and (p=0.0288, Pearson’s 
chi-squared test) respectively (Table 2). 
 
Out of 96 patients who were prescribed above threshold CS, 66 (68.8%) received 
immunomodulatory therapy (IMT) in the past 12 months. By comparison, a significantly 
lower proportion of patients (88/189, 46.6%) treated with below threshold CS, received IMT 
(p<0.001, Pearson’s chi-squared test). (Table 3, Supplementary Information). Patients in both 
groups (above and below threshold) took biologic therapies and conventional IMTs at similar 
frequencies and doses respectively (Tables 3 and 4 Supplementary information). The doses of 





A second uveitis expert reviewed clinical records using a semi-objective scoring matrix from 
a total of 52/96 patients who met criteria for above threshold CS prescribing from 5 
participating centres to a) identify reasons for excess CS prescribing and b) to determine 
whether this might have been avoided. (Table 1). The use of excess CS was judged avoidable 
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in 13/52 patients (25%), typically when there was an opportunity to reasonably curtail CS 
dose (Table 1). Of those 13 patients, 12 were treated with an excess maintenance dose of CS, 




This cross-sectional study included 667 patients, from 11 uveitis practices in the UK and is the 
first attempt at a country-wide analysis of CS prescribing practices, made possible by The Uveitis 
Clinical Study Group[8], a large clinical research network of uveitis specialists within the UK.  
 
Overall, 42.7% of patients were treated with oral CS for non-infectious uveitis excluding acute 
anterior uveitis and masquerade syndromes in the 12 months preceding their entry into the study. 
Of patients treated with CS (n=285) within this cohort, more than a third (38.9%) received at 
least one systemic course of high dose CS on one occasion over the preceding 12 months. The 
extent to which systemic CS is prescribed partly reflects that it is first-line therapy for ocular 
inflammation during induction or for flares of sight-threatening uveitis[12]. The use of 
intraocular CS implants was small (5.2%) over the preceding 12 months. 
   
Using criteria for excess maintenance CS endorsed by international consensus guidance and a 
pragmatic criterion for excess courses of high dose steroids adopted from British Society of 
Gastroenterology guidelines[7], we found that a third of patients (33.7%) taking CS within this 
study met the criteria for excess CS prescribing for ocular inflammation. Most excess steroid 
prescribing was for maintenance treatment (n=84, 29.5% of patients treated with CS). In a study 
on CS-induced osteoporosis in 2002 in 129 uveitis patients from five tertiary referral uveitis 
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centres in England, treatment time with prednisolone varied from 13 weeks to 31 years. The 
mean dose was 13.6mg/day (range 2.8-41) with a mean cumulative dose of 16,849mg. Bone 
density was abnormally low in 44.2%, and 15.5% had osteoporosis. Bone loss correlated 
with total steroid dose, mean dose, duration of treatment and the presence of pre-existing 
risk factors[13]. In a survey of prescribing practices of 63 US physicians treating patients with 
uveitis published in 2011, the mean initial dose of CS prescribed was 44mg, tapered to 34mg/day 
as a maintenance dose. Interestingly, 75% of surveyed physicians in this study were unaware of 
consensus guidelines[14]. In our cohort, the median maximum dose of CS prescribed in the past 
12 months was 10mg for those treated below threshold (mean 23mg) and 40mg for those treated 
above threshold (mean 40mg). At the ‘study visit’, the median dose was 5mg for those treated 
below threshold and 10mg for those treated above threshold.  
 
We did not find evidence for under-treatment with IMTs in patients who exceeded the threshold 
for high dose CS with respect to dose or number of immunomodulatory agents. (Tables 3 and 4, 
Supplementary Information). In the UK, adalimumab is the only licensed systemic therapy for 
use in non-infectious uveitis, although conventional IMTs are widely used off-label. Other 
biologic agents are not licensed and are only available in very limited circumstances such as 
Behcet’s disease[15]. Our data support the contention that there are insufficient therapies 
routinely available to spare CS exposure in uveitis. In the US, an evaluation of insurance claims, 
pointed to more ocular complications in uveitis patients than age-matched controls, reflecting 
insufficient available therapy[16]. Thus, uveitis and scleritis remain areas of unmet need 
particularly compared to other inflammatory diseases. 
  
The analysis during phase 2 of this study found that excess CS prescribing might be avoided in 
one quarter of cases. These results suggest that there is opportunity to reduce the proportion of 
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those exposed to large doses of CS, particularly as part of maintenance therapy. It is possible that 
greater awareness among prescribers of consensus guidance, greater utilisation of steroid-sparing 
therapies, local therapies, and increased communication with patients may reduce exposure to CS 
where they are not clinically necessary. 
 
Although there is no specific consensus guidance for courses of high dose systemic CS therapy in 
patients with uveitis or scleritis, a small percentage (8.1%) of the cohort receiving CS, were 
prescribed more than 1 course of high dose CS within a year. In the context of well-established 
risks of CS therapy, guidance on a desirable limit to the number of courses of high dose CS is 
appropriate. Attempting to limit CS to 1 high dose course per year and a maximal maintenance 
dose of 7.5mg prednisolone/ day would serve as a pragmatic means of minimising excess 
exposure to CS within uveitis practice and also reflects current prescribing for the majority of 
patients in the UK. 
 
This is the first study to investigate adherence to international consensus guidance for CS 
prescribing. We demonstrate significant dependence on CS in uveitis patients at maintenance 
doses of more than a dose of 7.5mg/day prednisolone and identify opportunity for reduction in 
CS exposure. We also recommend a modification of current guidelines to include a maximum of 
1 high dose CS course per year. The high rate of concomitant use of immunomodulatory therapy 
in those meeting the criteria for excess systemic CS exposure, suggests that in some cases, a 
higher dose of CS may be necessary due to inadequate control of intraocular inflammation 
despite existing immunosuppressive strategies. This underlines the need for greater availability of 
therapies to treat ocular inflammation. 
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The strengths of this study were that: a large number of consecutive uveitis patients were 
included, from multiple centres, data were collected during the preceding 12 months and reflect 
prescribing practices in principally tertiary uveitis centres in England. A possible limitation of 
this study is that the 6-week period of patient enrolment may have been too short, and a longer 
window would have generated a larger cohort of patients that could have been more 
representative of clinical practice. The study did not mandate how consecutive uveitis patients 
were identified, which varied between sites, and may have introduced bias if patients were 
missed. It is possible that CS prescribing practice within non-specialist centres and in other 
countries may differ from the findings in this study and that our findings are an underestimate of 
excessive corticosteroid prescribing.  
 
Using a national clinical network of uveitis specialists[8], we were able to report prescribing 
practices for CS, a medication class which is associated with both a poor tolerability profile in 
patients and significant long-term morbidity. Our data reflects the role of systemic CS in the 
current management of chronic non-infectious uveitis and offers insights into both adherence to 
existing CS prescribing guidance and the clinical settings in which prescribing decisions are 
made. Using a target maximum maintenance dose of 7.5mg/day, or equivalent, of prednisolone, 
which is consistent with international consensus guidelines[5], and a pragmatic target of no more 
than a single rescue treatment of CS over a 12-month period, about one third of patients received 
excess CS. A closer assessment of clinical decision-making suggests that there may be 
opportunity to reduce excess CS prescribing in a quarter of cases. This study also highlights that 
uveitis remains an area of unmet medical need, where CS may be over-utilised as a means of 
reducing the risk of sight loss in the absence of a sufficient range of effective therapies. 
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Titles and Legends to Figures 
 
Figure 1: Study Diagram for Phase 1 and Phase 2 (CS= corticosteroid; IMT = 
immunomodulatory therapy)  
 
Figure 2: Distribution of CS use over 12 months (CS = corticosteroid) 
 
 
